Prognosis of multiple sclerosis: Clinical factors predicting the late evolution for an early treatment decision

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

With the development of new immunomodulating therapies, with which early use is strongly encouraged, it is crucial to be in possession of reliable clinical predictors of multiple sclerosis evolution. Prognostic factors are important to patients wanting to be informed about their prospects; to the clinician needing to individualize patients requiring immune treatments at an early stage of the disease; and also to the researcher needing to to improve the design and analysis of the clinical therapeutic trials and observational studies. Frequentist analyses have indicated a poor prognosis for male gender, late age at onset, motor, cerebellar and sphincter involvement at onset, progressive course at onset, short inter-attack interval, high number of early attacks; and a relevant early residual disability. A recent application of a Bayesian analysis led to the construction of more detailed models of the natural history of multiple sclerosis and the estimated risk of unfavorable evolution at an individual patient level.

Original languageEnglish
Pages (from-to)357-364
Number of pages8
JournalExpert Review of Neurotherapeutics
Volume6
Issue number3
DOIs
Publication statusPublished - Mar 2006

Fingerprint

Multiple Sclerosis
Bayes Theorem
Age of Onset
Observational Studies
Therapeutics
Research Personnel
Clinical Trials

Keywords

  • β-interferon
  • Bayesian analysis
  • Clinical factors
  • Glatiramer acetate
  • Immunomodulating therapies
  • Multiple sclerosis
  • Natural history
  • Poor outcome
  • Prognosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

@article{608e39f0dbe64f60b5e7dbeda9f4b7f9,
title = "Prognosis of multiple sclerosis: Clinical factors predicting the late evolution for an early treatment decision",
abstract = "With the development of new immunomodulating therapies, with which early use is strongly encouraged, it is crucial to be in possession of reliable clinical predictors of multiple sclerosis evolution. Prognostic factors are important to patients wanting to be informed about their prospects; to the clinician needing to individualize patients requiring immune treatments at an early stage of the disease; and also to the researcher needing to to improve the design and analysis of the clinical therapeutic trials and observational studies. Frequentist analyses have indicated a poor prognosis for male gender, late age at onset, motor, cerebellar and sphincter involvement at onset, progressive course at onset, short inter-attack interval, high number of early attacks; and a relevant early residual disability. A recent application of a Bayesian analysis led to the construction of more detailed models of the natural history of multiple sclerosis and the estimated risk of unfavorable evolution at an individual patient level.",
keywords = "β-interferon, Bayesian analysis, Clinical factors, Glatiramer acetate, Immunomodulating therapies, Multiple sclerosis, Natural history, Poor outcome, Prognosis",
author = "Roberto Bergamaschi",
year = "2006",
month = "3",
doi = "10.1586/14737175.6.3.357",
language = "English",
volume = "6",
pages = "357--364",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Prognosis of multiple sclerosis

T2 - Clinical factors predicting the late evolution for an early treatment decision

AU - Bergamaschi, Roberto

PY - 2006/3

Y1 - 2006/3

N2 - With the development of new immunomodulating therapies, with which early use is strongly encouraged, it is crucial to be in possession of reliable clinical predictors of multiple sclerosis evolution. Prognostic factors are important to patients wanting to be informed about their prospects; to the clinician needing to individualize patients requiring immune treatments at an early stage of the disease; and also to the researcher needing to to improve the design and analysis of the clinical therapeutic trials and observational studies. Frequentist analyses have indicated a poor prognosis for male gender, late age at onset, motor, cerebellar and sphincter involvement at onset, progressive course at onset, short inter-attack interval, high number of early attacks; and a relevant early residual disability. A recent application of a Bayesian analysis led to the construction of more detailed models of the natural history of multiple sclerosis and the estimated risk of unfavorable evolution at an individual patient level.

AB - With the development of new immunomodulating therapies, with which early use is strongly encouraged, it is crucial to be in possession of reliable clinical predictors of multiple sclerosis evolution. Prognostic factors are important to patients wanting to be informed about their prospects; to the clinician needing to individualize patients requiring immune treatments at an early stage of the disease; and also to the researcher needing to to improve the design and analysis of the clinical therapeutic trials and observational studies. Frequentist analyses have indicated a poor prognosis for male gender, late age at onset, motor, cerebellar and sphincter involvement at onset, progressive course at onset, short inter-attack interval, high number of early attacks; and a relevant early residual disability. A recent application of a Bayesian analysis led to the construction of more detailed models of the natural history of multiple sclerosis and the estimated risk of unfavorable evolution at an individual patient level.

KW - β-interferon

KW - Bayesian analysis

KW - Clinical factors

KW - Glatiramer acetate

KW - Immunomodulating therapies

KW - Multiple sclerosis

KW - Natural history

KW - Poor outcome

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=33645874210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645874210&partnerID=8YFLogxK

U2 - 10.1586/14737175.6.3.357

DO - 10.1586/14737175.6.3.357

M3 - Article

C2 - 16533140

AN - SCOPUS:33645874210

VL - 6

SP - 357

EP - 364

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 3

ER -